Q2 EPS Forecast for Keros Therapeutics Decreased by Analyst

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities research analysts at William Blair reduced their Q2 2025 earnings estimates for shares of Keros Therapeutics in a research report issued on Tuesday, May 6th. William Blair analyst M. Phipps now forecasts that the company will earn ($1.08) per share for the quarter, down from their prior forecast of ($0.81). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at $0.51 EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($2.90) EPS and FY2028 earnings at ($2.63) EPS.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. During the same period last year, the company earned ($1.21) EPS.

Several other research firms have also issued reports on KROS. Cantor Fitzgerald lowered Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Oppenheimer lowered their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Wedbush reissued a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. Finally, Truist Financial lowered their target price on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.67.

Keros Therapeutics Stock Down 2.6 %

NASDAQ:KROS opened at $13.65 on Friday. The firm has a market capitalization of $554.39 million, a P/E ratio of -2.62 and a beta of 1.32. The company has a fifty day moving average of $12.20 and a 200-day moving average of $24.71. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $72.37.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently added to or reduced their stakes in KROS. Vanguard Group Inc. lifted its position in shares of Keros Therapeutics by 31.1% during the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock worth $26,151,000 after buying an additional 609,212 shares during the last quarter. XTX Topco Ltd bought a new stake in Keros Therapeutics during the 1st quarter worth approximately $490,000. Federated Hermes Inc. raised its holdings in shares of Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock valued at $12,474,000 after purchasing an additional 1,099,519 shares during the last quarter. Corton Capital Inc. bought a new position in Keros Therapeutics in the 1st quarter valued at $186,000. Finally, CWM LLC lifted its stake in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after purchasing an additional 2,641 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.